Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report)’s share price rose 5% during trading on Monday . The company traded as high as $12.33 and last traded at $12.4860. 515,751 shares were traded during mid-day trading, a decline of 68% from the average daily volume of 1,605,940 shares. The stock had previously closed at $11.89.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the stock. Morgan Stanley set a $24.00 target price on shares of Kura Oncology in a report on Monday. CLSA set a $24.00 price target on shares of Kura Oncology in a report on Thursday, June 4th. Oppenheimer set a $24.00 price objective on shares of Kura Oncology in a research report on Thursday, May 28th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research note on Monday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.40.
View Our Latest Analysis on Kura Oncology
Kura Oncology Price Performance
Kura Oncology (NASDAQ:KURA – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. The company had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. On average, equities research analysts predict that Kura Oncology, Inc. will post -3.23 earnings per share for the current year.
Insider Activity at Kura Oncology
In other Kura Oncology news, insider Teresa Brophy Bair sold 31,487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total value of $397,680.81. Following the sale, the insider owned 195,444 shares in the company, valued at approximately $2,468,457.72. This trade represents a 13.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider directly owned 182,345 shares in the company, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.60% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Kura Oncology
A number of institutional investors and hedge funds have recently added to or reduced their stakes in KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after acquiring an additional 2,977 shares in the last quarter. Strs Ohio acquired a new position in shares of Kura Oncology during the first quarter valued at $143,000. Legal & General Group Plc increased its holdings in shares of Kura Oncology by 35.1% during the second quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after purchasing an additional 18,930 shares during the period. Rhumbline Advisers raised its stake in shares of Kura Oncology by 13.0% during the second quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock valued at $686,000 after purchasing an additional 13,690 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Kura Oncology by 244.5% during the second quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock valued at $1,343,000 after purchasing an additional 165,189 shares in the last quarter.
Kura Oncology Company Profile
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Featured Articles
- Five stocks we like better than Kura Oncology
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
- If Boeing Ramps Up Production, These Suppliers May Win Big
- Marvell Takes a Shot a Broadcom’s Throne With Google Deal
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
